Bayer and Genaissance eye individualised medicine:
This article was originally published in Clinica
Bayer Diagnostics has formed a deal with Genaissance Pharmaceuticals to develop diagnostic tests for determining adverse drug response and efficacy response to existing drug classes and new drug products. Genaissance will apply its haplotype technology, HAP, to Bayer's clinical samples in order to identify diagnostic markers and therapeutic targets for individualised medicine. Bayer will receive exclusive rights to develop and market tests based on the results of the collaboration. Genaissance will receive royalties and rights to perform these tests in its CLIA-certified diagnostic laboratory. There are mutual royalty provisions for any drugs derived from the co-operation.